-
- Jul 14, 2020
Visual acuity improvement after aflibercept injection maintained over 3 years
Long-term aflibercept injection achieve visual improvement and reduced the thickness of the retina and choroid in patients with neovascular age-related macular degeneration (nAMD), according to a study published in BMC Ophthalmology.
In this prospective study, 49 patient…
-
- Jul 12, 2020
FDA approves treatment for blepharoptosis
The U.S. Food and Drug Administration has approved oxymetazoline hydrochloride ophthalmic solution 0... -
- Jul 12, 2020
FDA accepts premarket approval application for DE-128 micros...
The U.S. Food and Drug Administration has accepted the premarket approval (PMA) application for DE-1...
VIDEOS
-
Jan 22, 2020
How do you Verify That a Patient…
-
Jan 22, 2020
Age-related Drusen or Pathologic…
-
Jan 22, 2020
What is DME?
-
Jan 22, 2020
ENTV DME Treatment Strategy
-
Jan 22, 2020
Study Review, Part 2: Continuous…
-
Jan 22, 2020
Study Review: Continuous…
Jan 22, 2020
Treating AMD Patients with New Technology
-
Age-related Drusen or Pathologic Drusen?
Jan 22, 2020
-
What is DME?
Jan 22, 2020
-
ENTV DME Treatment Strategy
Jan 22, 2020
Conference Roundup
- Jun 25, 2020
ASCRS changes date of 2021 meeting
The 2021 American Society of Cataract and Refractive Surgery (ASCRS) meeting has been rescheduled from April to August, according to a statement from ASCRS.
The meeting will now be new held August 13-17 in San Francisco, CA.…
Continuing Medical Education
Journal Scan
- Jul 14, 2020
Visual acuity improvement after aflibercept injection maintained over 3 years
Long-term aflibercept injection achieve visual improvement and reduced the thickness of the retina and choroid in patients with neovascular age-related macular degeneration (nAMD), according to a study published in BMC Ophthalmology. …
-
-
-
-
AAO launching open-access journal
Jul 03, 2020
Trending Topics
- Jul 12, 2020
FDA approves treatment for blepharoptosis
The U.S. Food and Drug Administration has approved oxymetazoline hydrochloride ophthalmic solution 0.1% (Upneeq; Osmotica Pharmaceuticals) for the treatment of acquired blepharoptosis, according to a press release.
This if the first FDA-approved…
Resources
-
Eye Care Organizations
- American Academy of Ophthalmic Executives
- American Academy of Ophthalmology
- American Association for Pediatric Ophthalmology and Strabismus
- American Glaucoma Society
- American Society of Cataract and Refractive Surgery
- American Society of Ophthalmic Administrators
- Contact Lens Association of Ophthalmologists
- Cornea Society
- Medical Group Management Association
- The Retina Society
-
Eye Care Tools
- AAPOS Vision Screening App
- ASCRS MACRA Center
- Cataract Surgery Risk Calculation Tool
- Clinical Decision-Making Algorithms for Glaucoma
- Cornea Transplant Database
- Diagnostic Tools for Dry Eye Disease
- Marketing Ophthalmology Services to Boost Business
- Post-Refractive IOL Calculator
- Practice Tools
- PRK, LASIK and SMILE Treatment Steps Graphic
- Professional Contact Lens Fee Calculator
- RetinaTalk Forum
